AI healthtech startup Deep 6 AI secures $17M Series A to accelerate clinical trial recruitment

Tens of thousands of clinical trials are registered with the FDA each year to evaluate new therapies, but many of them fail to identify and recruit enough patients in a timely manner to clinically validate the efficacy of the treatment under study. The process of evaluating patients against a trial’s complex recruitment criteria is extremely time-consuming and inefficient, requiring full-time staff dedicated to combing through patient records, one at a time. As a consequence of this inefficiency, over 85% of trials are delayed and many trials ultimately fail due to poor recruitment.

Enter Deep 6 AI, an artificial intelligence-based healthtech startup and a provider of clinical trials acceleration software. Using artificial intelligence on medical records, Deep 6 AI finds more, better-matching patients for clinical trials in minutes, not months, getting life-saving cures to patients more quickly.

Yesterday, Deep 6 AI announced it has raised $17M in Series A funding to accelerate the growth of its network of leading healthcare providers and trial sponsors and keep expanding its suite of innovative, AI-native software products. The round was led by Point72 Ventures, with GSR Ventures and strategic partners participating. The investment will build the company’s capacity to meet demand from healthcare providers, pharma companies, and contract research organizations for the company’s suite of AI-driven tools designed to accelerate and optimize clinical trials design, recruitment, and management.

Founded in 2015, the Pasadena, California-based Deep 6 AI also helps sponsors and CROs with better trial feasibility design, site selection, real-time analysis of study results, and improved trial response rates, from selecting better-matching trial subjects. Deep 6 AI is a Techstars, StartX, and TMCx alum and is currently in use by leading hospitals, such as Cedars-Sinai Medical Center, the Texas Medical Center, and other research institutes, life sciences companies and CROs.

Deep 6 AI’s customers today include Cedars Sinai Medical Center and Texas Medical Center, among several other large health systems across the U.S., in addition to a number of large life sciences companies, medical device companies and contract research organizations.

“We see clinical trials recruiting as a place where a data and AI-driven approach holds tremendous promise in accelerating life-saving research,” said Point72 Ventures partner Daniel Gwak. “Deep 6’s track record in accelerating clinical trials through improved patient recruitment and trial design has resonated strongly with major healthcare providers and trial sponsors, who recognize Deep 6 as the clear leader in this field. We are excited to support them in scaling up to meet demand as more organizations recognize the need for and value from Clinical Trials Acceleration software.” As part of this investment, Daniel Gwak will join the Deep 6 AI Board of Directors.

“We are very excited to partner with Point72 Ventures to pursue our vision to build the leading global clinical trials acceleration software platform. Point72 Ventures’ emphasis on backing best-in-class category leaders validates Deep 6’s reputation as the product and technology leader in this new industry,” said Deep 6 AI CEO, Wout Brusselaers. “Their investment will allow us to rapidly scale up to meet the high demand for our software, as health systems recognize the significant opportunity from leveraging AI to turn their research efforts into a growth and profit center.”